Support will further the development of a transperineal prostate fusion platform
The contribution will support the research and development of a new transperineal prostate fusion platform that allows physicians to better target specific areas of the prostate for the purpose of diagnosing and treating prostate cancer. By offering a highly targeted approach to managing prostate cancer, patients can get more timely diagnoses and receive focalized treatment that has the potential to improve their standards of living.
“We are grateful for the advice and funding support from NRC IRAP as it will help us accelerate the research and development of our transperineal platform,” said Chicuong La, CEO of Focal Healthcare. “The support will allow us to incorporate elements of artificial intelligence and automation into this new device and other products that will make them even easier to use and more accurate.
Focal Healthcare’s current product, Fusion Bx 2.0, combines information from multiparametric MRI with a semi-robotic arm and user-friendly interface to give physicians the ability to perform targeted prostate biopsies. Fusion Bx 2.0 is cleared for sale in Canada, USA, the EU and Taiwan.
This project will support the development of a fully automated transperineal MRI fusion device towards enabling clinical trials.
About Focal Healthcare Inc.
Focal Healthcare is a Canadian-based medical device company committed to improving the lives of prostate cancer patients and their families through technical innovation. By developing imaging tools that emphasize accuracy, efficiency and accessibility, Focal Healthcare strives to advance prostate cancer diagnosis and management in clinics and hospitals of all sizes. Focal Healthcare designs and manufactures all its products at its headquarters in Toronto, Canada.